Pipeline

Conventional disease-modifying medicines cannot reverse disease…

While conventional disease-modifying medicines can slow pathologic, symptomatic and functional decline, they cannot reverse disease and may suppress repair. By supporting restorative cells and selectively targeting metabolically constrained aggressor cells, our approach not only inhibits auto-inflammation but also enables normal tissue repair. This has the potential to go beyond conventional disease modification by rebuilding damaged tissue to restore normal architecture.

Our pipeline consists of programmed disease-resolving drugs, offering novel treatments for a wide range of disorders. Our lead investigational drug, leramistat, moves the interventional needle from disease modification to disease resolution, helping patients not only reduce symptoms but reverse their decline, regaining lost functionality.

Drug/Disease
Discovery Pre-clinical Phase 1 Phase 2 Phase 3

Discovery Pre-clinical Phase 1 Phase 2 Phase 3

Leramistat is an investigational first-in-class, once-daily pill that works in an exciting new way, with strong promising results in bone and joint damage repair and protection without suppressing the immune system. A notable departure from current RA treatment approaches, leramistat works by augmenting the body’s inherent repair response to repair and restore damaged tissue as well as build resilience to cycles of further destruction. Our research suggests that the striking tissue repair benefits of leramistat could positively impact multiple chronic conditions of autoimmunity, fibrosis and bone loss.

Discovery Pre-clinical Phase 1 Phase 2 Phase 3

Leramistat has been granted both FDA Fast Track and Orphan Drug Designation (ODD) to support its development and expedite its review to fulfil an unmet medical need in IPF. You can access our expanded access policy here.

Discovery Pre-clinical Phase 1 Phase 2 Phase 3

Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum.

Discovery Pre-clinical Phase 1 Phase 2 Phase 3

Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum.